Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice

Journal of Medical Virology

Volumn 85, Issue 6, 2013, Pages 996-1004

  Salpini, R ^a   Alteri, C ^a   Cento, V ^a   Pollicita, M ^a   Micheli, V ^b   Gubertini, G ^b   De Sanctis, G M ^c   Visca, M ^d   Romano, S ^d   Sarrecchia, C ^e   Andreoni, M ^e   Angelico, M ^e   Parruti, G ^f   Svicher, V ^a   Perno, C F ^a,e  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SANDRO PERTINI HOSPITAL   (Italy)

^e TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^f SPIRITO SANTO HOSPITAL   (Italy)

Author keywords

Drug resistance; Genotypic testing; HBV D and A genotype; NUCs treatment

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL PRACTICE; DRUG POTENCY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; VIRUS DETECTION;

ADENINE; ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; RECURRENCE; THYMIDINE; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 84876388567     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23567     Document Type: Article

References (30)

1. Chang TT, Lai CL, Kew YS, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. 2010. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51: 422-430.
2. Fasano M, Lampertico P, Marzano A, Di Marco V, Niro GA, Brancaccio G, Marengo A, Scotto G, Brunetto MR, Gaeta GB, Rizzetto M, Angarano G, Santantonio T. 2012. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol 56: 1254-1258.
3. Ghany MG, Doo EC. 2009. Antiviral resistance and hepatitis B therapy. Hepatology 49: S174-S184.
4. Ghany M, Liang TJ. 2007. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132: 1574-1585.
5. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL. 2006. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131: 1743-1751.
6. Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T, Lok AS. 2011. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 53: 1854-1863.
7. Ji D, Liu Y, Li L, Xu Z, Si LL, Dai JZ, Li X, Wang L, Yao Z, Xin SJ, Chen GF, Xu D. 2012. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation. J Clin Virol 54: 66-72.
8. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H. 2008. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 6: 1315-1341.
9. Lai MW, Yeh CT. 2008. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 13: 875-879.
10. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36, 687-696.
11. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV. 2009. 2-Year GLOBE trial results: Telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136: 486-495.
12. Liaw YF, Brunetto MR, Hadziyannis S. 2010. The natural history of chronic HBV infection and geographical differences. Antivir Ther 15: 25-33.
13. Lin CL, Chien RN, Hu CC, Lai MW, Yeh CT. 2012. Identification of hepatitis B virus rtS117F substitution as a compensatory mutation for rtM204I during lamivudine therapy. J Antimicrob Chemother 67: 39-48.
14. Liu J-H, Liu Y, Xu ZH, Wang Y, Chen L, Li L, Yao ZT, Hu JX. 2012. Identification and analysis of phenotypic resistance characteristics of a novel mutation rtL180M+A181C+M204V in HBV reverse-transcriptase region of a patient with chronic hepatitis B. Med J Chin People's Liberation Army 6: 552-555.
15. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125: 1714-1722.
16. Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F. 2008. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 48: 750-758.
17. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, van Bömmel, F, Hansen BE, Wedemeyer H, Janssen HL. 2010. Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. J Hepatol 52: 493-500.
18. Salpini R, Svicher V, Cento V, Gori C, Bertoli A, Scopelliti F, Micheli V, Cappiello T, Spano A, Rizzardini G, De Sanctis GM, Sarrecchia C, Angelico M, Perno CF. 2011. Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naive to antiviral drugs. Antiviral Res 92: 382-385.
19. Sayan M, Akhan SC, Senturk O. 2011. Frequency and mutation patterns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogs in add-on and switch strategies. Hepat Mon 11: 835-842.
20. Sheldon J, Soriano V. 2008. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 61: 766-768.
21. Svicher V, Gori C, Trignetti M, Visca M, Micheli V, Bernassola M, Salpini R, Gubertini G, Longo R, Niero F, Ceccherini-Silberstein F, De Sanctis GM, Spano A, Cappiello G, Perno CF. 2009. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J. Hepatol 50: 461-470.
22. Svicher V, Alteri C, Gori C, Salpini R, Marcuccilli F, Bertoli A, Longo R, Bernassola M, Gallinaro V, Romano S, Visca M, Ursitti A, Feasi M, Micheli V, Angelico M, Cassola G, Parruti G, Gubertini G, De Sanctis GM, Ceccherini-Silberstein F, Cappiello G, Spano A, Perno CF. 2010. Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia. Dig Liver Dis 42: 902-907.
23. Svicher V, Cento V, Salpini R, Mercurio F, Fraune M, Beggel B, Han Y, Gori C, Wittkop L, Bertoli A, Micheli V, Gubertini G, Longo R, Romano S, Visca M, Gallinaro V, Marino N, Mazzotta F, De Sanctis GM, Fleury H, Trimoulet P, Angelico M, Cappiello G, Zhang XX, Verheyen J, Ceccherini-Silberstein F, Perno CF. 2011. Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis 43: 975-983.
24. Svicher V, Cento V, Bernassola M, Neumann-Fraune M, Van Hemert F, Chen M, Salpini R, Liu C, Longo R, Visca M, Romano S, Micheli V, Bertoli A, Gori C, Ceccherini-Silberstein F, Sarrecchia C, Andreoni M, Angelico M, Ursitti A, Spano A, Zhang JM, Verheyen J, Cappiello G, Perno CF. 2012. Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. Antiviral Res 93: 86-93.
25. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739.
26. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T, Jackson DC. 2002. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293: 305-313.
27. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Huppe D, Stein K, Trojan J, Sarrazin C, Bocher WO, Spengler U, Wasmuth HE, Reinders JG, Moller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. 2010. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51: 73-80.
28. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, Zoulim F. 2008. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 48: 747-755.
29. Yang JX, Liu BM, Li XG, Yan CH, Xu J, Sun XW, Wang YH, Jiao XJ, Yan L, Dong JP, Hou CS, Abuduheilili X, Li T, Zhuang H. 2010. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients. Antivir Ther 15: 1171-1178.
30. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137: 1593-1608.